Thrombosis in systemic lupus erythematosus

Congenital and acquired risk factors

Antonella Afeltra, Marta Vadacca, Laura Conti, Sara Galluzzo, Anna P. Mitterhofer, Giovanni M. Ferri, Flavia Del Porto, Domenico Caccavo, Giuseppe M. Gandolfo, Antonio Amoroso

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective. To investigate the thrombotic tendency in patients with systemic lupus erythematosus (SLE) by evaluating congenital or acquired abnormalities associated with an increased risk of venous and/or arterial thrombosis. Methods. A total of 57 patients with SLE were included in the study. Twenty-one patients (37%) had a history of arterial and/or venous thrombosis and 36 patients (63%) did not have such a history. Sera from 50 healthy controls were examined. Protein C, protein S, antithrombin, D-dimer, fibrinogen, homocysteine, anticardiolipin antibodies (aCL), lupus anticoagulant (LAC), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation were evaluated. Results. Protein C, antithrombin, fibrinogen, D-dimer, and homocysteine levels were significantly higher in patients with SLE than in controls. A prothrombin mutation was observed in 2 (4%) of 50 controls and in 6 (11%) of 57 patients. A significantly higher prevalence (P = 0.036) of MTHFR homozygous mutation was observed in patients with SLE (14 [25%] of 57) in comparison with controls (4 [8%] of 50). IgG-aCL and IgM-aCL levels were significantly higher in patients with SLE than in controls (P <0.0001). The presence of medium-high (≥20 IgG phospholipid units/ml) IgG-aCL antibody titers was significantly higher (P = 0.005) in patients with thrombosis (11 [52%] of 21) than in patients without (5 [14%] of 36) thrombosis. LAC was present in 22 (38.5%) of 57 patients and in none of 50 controls. Conclusion. In this study, we confirm the association between thrombosis and IgG-aCL at medium-high titers and suggest that the coexistence of other risk factors can affect the expression of thrombosis in patients with SLE.

Original languageEnglish
Pages (from-to)452-459
Number of pages8
JournalArthritis Care and Research
Volume53
Issue number3
DOIs
Publication statusPublished - Jun 15 2005

Fingerprint

Systemic Lupus Erythematosus
Thrombosis
Anticardiolipin Antibodies
Immunoglobulin G
Methylenetetrahydrofolate Reductase (NADPH2)
Lupus Coagulation Inhibitor
Antithrombins
Prothrombin
Homocysteine
Protein C
Fibrinogen
Mutation
Protein S
Venous Thrombosis
Immunoglobulin M
Phospholipids
History
Antibodies

Keywords

  • Risk factors
  • Systemic lupus erythematosus
  • Thrombosis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Afeltra, A., Vadacca, M., Conti, L., Galluzzo, S., Mitterhofer, A. P., Ferri, G. M., ... Amoroso, A. (2005). Thrombosis in systemic lupus erythematosus: Congenital and acquired risk factors. Arthritis Care and Research, 53(3), 452-459. https://doi.org/10.1002/art.21172

Thrombosis in systemic lupus erythematosus : Congenital and acquired risk factors. / Afeltra, Antonella; Vadacca, Marta; Conti, Laura; Galluzzo, Sara; Mitterhofer, Anna P.; Ferri, Giovanni M.; Del Porto, Flavia; Caccavo, Domenico; Gandolfo, Giuseppe M.; Amoroso, Antonio.

In: Arthritis Care and Research, Vol. 53, No. 3, 15.06.2005, p. 452-459.

Research output: Contribution to journalArticle

Afeltra, A, Vadacca, M, Conti, L, Galluzzo, S, Mitterhofer, AP, Ferri, GM, Del Porto, F, Caccavo, D, Gandolfo, GM & Amoroso, A 2005, 'Thrombosis in systemic lupus erythematosus: Congenital and acquired risk factors', Arthritis Care and Research, vol. 53, no. 3, pp. 452-459. https://doi.org/10.1002/art.21172
Afeltra, Antonella ; Vadacca, Marta ; Conti, Laura ; Galluzzo, Sara ; Mitterhofer, Anna P. ; Ferri, Giovanni M. ; Del Porto, Flavia ; Caccavo, Domenico ; Gandolfo, Giuseppe M. ; Amoroso, Antonio. / Thrombosis in systemic lupus erythematosus : Congenital and acquired risk factors. In: Arthritis Care and Research. 2005 ; Vol. 53, No. 3. pp. 452-459.
@article{8ba8908f458d40d8b0b42596ace73084,
title = "Thrombosis in systemic lupus erythematosus: Congenital and acquired risk factors",
abstract = "Objective. To investigate the thrombotic tendency in patients with systemic lupus erythematosus (SLE) by evaluating congenital or acquired abnormalities associated with an increased risk of venous and/or arterial thrombosis. Methods. A total of 57 patients with SLE were included in the study. Twenty-one patients (37{\%}) had a history of arterial and/or venous thrombosis and 36 patients (63{\%}) did not have such a history. Sera from 50 healthy controls were examined. Protein C, protein S, antithrombin, D-dimer, fibrinogen, homocysteine, anticardiolipin antibodies (aCL), lupus anticoagulant (LAC), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation were evaluated. Results. Protein C, antithrombin, fibrinogen, D-dimer, and homocysteine levels were significantly higher in patients with SLE than in controls. A prothrombin mutation was observed in 2 (4{\%}) of 50 controls and in 6 (11{\%}) of 57 patients. A significantly higher prevalence (P = 0.036) of MTHFR homozygous mutation was observed in patients with SLE (14 [25{\%}] of 57) in comparison with controls (4 [8{\%}] of 50). IgG-aCL and IgM-aCL levels were significantly higher in patients with SLE than in controls (P <0.0001). The presence of medium-high (≥20 IgG phospholipid units/ml) IgG-aCL antibody titers was significantly higher (P = 0.005) in patients with thrombosis (11 [52{\%}] of 21) than in patients without (5 [14{\%}] of 36) thrombosis. LAC was present in 22 (38.5{\%}) of 57 patients and in none of 50 controls. Conclusion. In this study, we confirm the association between thrombosis and IgG-aCL at medium-high titers and suggest that the coexistence of other risk factors can affect the expression of thrombosis in patients with SLE.",
keywords = "Risk factors, Systemic lupus erythematosus, Thrombosis",
author = "Antonella Afeltra and Marta Vadacca and Laura Conti and Sara Galluzzo and Mitterhofer, {Anna P.} and Ferri, {Giovanni M.} and {Del Porto}, Flavia and Domenico Caccavo and Gandolfo, {Giuseppe M.} and Antonio Amoroso",
year = "2005",
month = "6",
day = "15",
doi = "10.1002/art.21172",
language = "English",
volume = "53",
pages = "452--459",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Thrombosis in systemic lupus erythematosus

T2 - Congenital and acquired risk factors

AU - Afeltra, Antonella

AU - Vadacca, Marta

AU - Conti, Laura

AU - Galluzzo, Sara

AU - Mitterhofer, Anna P.

AU - Ferri, Giovanni M.

AU - Del Porto, Flavia

AU - Caccavo, Domenico

AU - Gandolfo, Giuseppe M.

AU - Amoroso, Antonio

PY - 2005/6/15

Y1 - 2005/6/15

N2 - Objective. To investigate the thrombotic tendency in patients with systemic lupus erythematosus (SLE) by evaluating congenital or acquired abnormalities associated with an increased risk of venous and/or arterial thrombosis. Methods. A total of 57 patients with SLE were included in the study. Twenty-one patients (37%) had a history of arterial and/or venous thrombosis and 36 patients (63%) did not have such a history. Sera from 50 healthy controls were examined. Protein C, protein S, antithrombin, D-dimer, fibrinogen, homocysteine, anticardiolipin antibodies (aCL), lupus anticoagulant (LAC), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation were evaluated. Results. Protein C, antithrombin, fibrinogen, D-dimer, and homocysteine levels were significantly higher in patients with SLE than in controls. A prothrombin mutation was observed in 2 (4%) of 50 controls and in 6 (11%) of 57 patients. A significantly higher prevalence (P = 0.036) of MTHFR homozygous mutation was observed in patients with SLE (14 [25%] of 57) in comparison with controls (4 [8%] of 50). IgG-aCL and IgM-aCL levels were significantly higher in patients with SLE than in controls (P <0.0001). The presence of medium-high (≥20 IgG phospholipid units/ml) IgG-aCL antibody titers was significantly higher (P = 0.005) in patients with thrombosis (11 [52%] of 21) than in patients without (5 [14%] of 36) thrombosis. LAC was present in 22 (38.5%) of 57 patients and in none of 50 controls. Conclusion. In this study, we confirm the association between thrombosis and IgG-aCL at medium-high titers and suggest that the coexistence of other risk factors can affect the expression of thrombosis in patients with SLE.

AB - Objective. To investigate the thrombotic tendency in patients with systemic lupus erythematosus (SLE) by evaluating congenital or acquired abnormalities associated with an increased risk of venous and/or arterial thrombosis. Methods. A total of 57 patients with SLE were included in the study. Twenty-one patients (37%) had a history of arterial and/or venous thrombosis and 36 patients (63%) did not have such a history. Sera from 50 healthy controls were examined. Protein C, protein S, antithrombin, D-dimer, fibrinogen, homocysteine, anticardiolipin antibodies (aCL), lupus anticoagulant (LAC), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation were evaluated. Results. Protein C, antithrombin, fibrinogen, D-dimer, and homocysteine levels were significantly higher in patients with SLE than in controls. A prothrombin mutation was observed in 2 (4%) of 50 controls and in 6 (11%) of 57 patients. A significantly higher prevalence (P = 0.036) of MTHFR homozygous mutation was observed in patients with SLE (14 [25%] of 57) in comparison with controls (4 [8%] of 50). IgG-aCL and IgM-aCL levels were significantly higher in patients with SLE than in controls (P <0.0001). The presence of medium-high (≥20 IgG phospholipid units/ml) IgG-aCL antibody titers was significantly higher (P = 0.005) in patients with thrombosis (11 [52%] of 21) than in patients without (5 [14%] of 36) thrombosis. LAC was present in 22 (38.5%) of 57 patients and in none of 50 controls. Conclusion. In this study, we confirm the association between thrombosis and IgG-aCL at medium-high titers and suggest that the coexistence of other risk factors can affect the expression of thrombosis in patients with SLE.

KW - Risk factors

KW - Systemic lupus erythematosus

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=20444378185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444378185&partnerID=8YFLogxK

U2 - 10.1002/art.21172

DO - 10.1002/art.21172

M3 - Article

VL - 53

SP - 452

EP - 459

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 3

ER -